Bruno Bastos, MD
Dr. Bruno Bastos is a medical oncologist who practices at the Miami Cancer Institute at Baptist Health in Miami, Florida. His clinical focus is on treatment of genitourinary cancers, diagnosing and treating patients with prostate cancer, bladder cancer, kidney cancer, ureter and urethra cancer, as well as other cancers including lung cancer and malignant peritoneal and pleural mesothelioma. He is actively involved in the use of advanced systemic therapies including chemotherapy, immunotherapy, hormone therapy, and targeted drug therapies.[1]
Dr. Bastos is board-certified in Internal Medicine, Medical Oncology, and Hematology and is a member of the American Society of Clinical Oncology. He also has extensive teaching experience.
Research
Dr. Bastos is actively involved in clinical research to discover new ways to treat cancer and improve patient outcomes. He serves as an editorial reviewer for numerous peer-reviewed medical journals, is widely published in those journals, and delivers invited lectures at numerous national and international scientific symposiums.[1]
His most recent publications include:[2]
Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 in a phase I clinical trial (NCT03829436). Feb 2024. Bruno R Bastos, Nathan Standifer, Rohan Garje, Sam H. Whiting. 438 Background: TPST-1120 is a first-in-class, oral inhibitor of peroxisome proliferator-activated receptor (PPAR-α), a fatty-acid ligand-activated transcriptional factor that controls the expression of multiple genes involved in fatty acid oxidation (FAO), angiogenesis and inflammation. In a phase 1 open-label trial, TPST-1120 was administered as…
Impact of TP53 , RB1 , and PTEN mutations on overall survival in metastatic prostate cancer: A multi-center study via the Guardian Research Network. Feb 2024. Mohammad Arfat Ganiyani, Pushan Prabhakar, Atulya Aman Khosla[…], Rohan Garje. 82 Background: The treatment paradigm for metastatic prostate cancer has significantly improved in the past decade. Nevertheless, there remains an unmet need for novel biomarker-driven risk stratification. Studies have shown that genetic alterations in any of the PTEN, RB1, and TP53 genes influence the prognosis, potential for androgen independence…
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Nov 2023. Benedito A. Carneiro, Ludimila Cavalcante, Devalingam Mahalingam[…], Pamela Munster. Purpose The safety, pharmacokinetics, and efficacy of elraglusib, a glycogen synthase kinase-3β (GSK-3β) small-molecule inhibitor, as monotherapy or combined with chemotherapy, in patients with relapsed or refractory solid tumors or hematologic malignancies was studied. Patients and Methods Elraglusib (intravenously twice weekly in 3-week cycles)…
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Jul 2023. Thomas W. Flaig, Catherine M Tangen. Siamak Daneshmand[…]. Seth P Lerner. Background: The COXEN gene expression model was evaluated for prediction of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). Objective: To conduct a secondary analysis of the association of each COXEN score with event-free survival (EFS) and overall survival (OS) and by treatment arm. Design, setting, and particip…
740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results,
Sep 2022. M. Gutierrez. C.F. Friedman. Georgina V Long[…], D.T. Le
